.png)
Onco-Summaries: Daily Oncology Updates at a Glance
- Oncofocus Team
- Oct 8
- 1 min read
07/10/2025
Precision NeuroMed's cinetredekin besudotox received the FDA orphan drug designation for GBM (Ref)
The US FDA granted the orphan drug designation to Precision NeuroMed's cinetredekin besudotox (IL13PE38 ; cytotoxic protein) for the treatment of glioblastoma (GBM).
The advanced convection-enhanced delivery (CED) platform delivers therapeutic concentrations of cinetredekin besudotox to tumor-infiltrated regions of the brain
Sandeep Kunwar, CEO and Co-Founder, Precision NeuroMed: "Receiving Orphan Drug Designation is an important milestone for Precision NeuroMed as we advance our mission to transform treatment for patients with glioblastoma, one of the most aggressive and devastating brain cancers. By combining innovative drugs with our next-generation delivery system, we hope to dramatically improve outcomes where few effective options currently exist."
Comments